<DOC>
	<DOCNO>NCT01092806</DOCNO>
	<brief_summary>One main side-effects tacrolimus solid organ transplant patient post transplant diabetes mellitus ( PTDM ) . It known different pharmacokinetic property influence risk develop PTDM . It possible either high peak concentration high overall systemic exponation responsible effect insulin secretion . With new slow-release formulation tacrolimus ( Advagraf ) different pharmacokinetic profile introduce patient interest investigate affect insulin secretion insulin sensitivity patient . Hypothesis : The pharmacokinetic profile tacrolimus affect insulin secretion renal transplant recipient .</brief_summary>
	<brief_title>Insulin Secretion Advagraf</brief_title>
	<detailed_description>Study objectives The primary objective compare insulin secretion ( Secr2.phase ) two different formulation Tac . Secondary objective compare effect two formulation Secr1.phase , insulin sensitivity investigate possible association individual systemic tacrolimus exposure . Study design Twenty adult kidney transplant patient treat Prograf® twice daily Advagraf® daily include study . Eligible patient may include stable posttransplant phase ( Tac dose adjustment acute rejection episode precede 2 week ) . A 3-hour hyperglycaemic clamp perform patient treated standard Tac formulation repeat 4-6 week switch alternative Tac formulation . The clamp investigation do administration morning dose Tac . Samples measurement Tac whole blood concentration draw patient 24 hour morning Tac dosing . It mandatory patient perform full 24 hour pharmacokinetic investigation . Switching alternative Tac formulation perform 1:1 daily dose ratio subsequently adjust accord centre protocol trough concentration ( 5-10 ng/mL ) . Patients meet trough concentration measurement Rikshospitalet appropriate dose adjustment period two investigation day . Patients The patient primarily recruit great-Oslo area study visit perform Rikshospitalet . Patients otherwise follow standard post transplant procedures local hospital study period . Patients include clinical trial also eligible inclusion present study long treat investigational drug . Informed consent obtain accord Declaration Helsinki ICH-GCP guideline . Patients investigator sign patient information keep file . The patient receive copy patient information . Patient data record Case Report Forms ( CRF ) information handle confidentially . Any complication record . Glucose clamp calculation Lean body mass ( lbm ) estimate use Hume 's formula [ 12 ] correlate well tritiated water electrical bioimpedance measure [ 13 ] . Secr1.phase calculate area serum insulin vs. time curve ( AUC , trapezoidal rule ) first 10 min clamp procedure , Secr2.phase calculate insulin AUC last hour ( 120-180 min ) clamp procedure . The calculation also perform C-peptide concentration . Glucose disposal rate ( GDR ) calculate amount glucose infuse last hour clamp . The IS index ( ISI ) calculate GDR [ mmol/kg ( lbm ) *min ] divide mean serum insulin ( pmol/l ) period . Glucose clearance calculate ISI divide mean serum glucose last 60 min clamp [ 14 ] . Pharmacokinetic calculation Nonlinear mixed effect model ( NONMEM software version VI Intel Fortran ( version 8 ) compilation tool ) use analyze dose-concentration-time data Tac use population approach . The pharmacokinetic profile data use develop pharmacokinetics model include effect major covariates ( e.g . age , gender , body size , renal function , hematocrit , acute rejection status etc . ) CL/F V/F 24-hour pharmacokinetics investigation . If applicable additional trough concentration data routine follow-up patient study use develop model . Exclusion patient data allow Tac concentration able measure accurately case unavailable information may interfere pharmacokinetic evaluation , e.g . exact blood sampling time dose give . The POSTHOC , MAXEVAL=0 option NONMEM use estimate individual AUC0-24 half-lives individual . Actually measure Ctrough , Cmax Tmax value also use describe pharmacokinetic property patient . Statistical consideration Sample size : Based assumption 15 % relative change insulin secretion two formulation clinically relevant relative standard deviation 25 % 20 patient need assure power 80 % 5 % significance level . Patients drop-out study substitute . Analysis plan : The primary end-point analyze per-protocol compare ratio insulin sensitivity ( Secr2.phase ) two formulation . Data transform obtain normal distribution appropriate . Secondary endpoint analyze follow : - Insulin Secr1.phase - Insulin sensitivity index ( ISI ) - Association insulin Secr2.phase , Secr1.phase ISI systemic exposure Tac ( derive individual NONMEM estimation ) - All analysis also perform C-peptide</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<criteria>Renal transplant recipient stable Tac base immunosuppressive therapy . 18 year age old . Stable prednisolone dose 5 mg/day less . Screatinine 150 umol/L . Signed informed consent . Acute rejection episode within last 2 week prior inclusion . Changes Tac dose within last 2 week prior inclusion . Diabetes mellitus ( WHO criteria ) . Pregnant nursing mother woman childbearing potential without acceptable contraception strategy . Concomitant treatment : diltiazem , verapamil , fenytoin , carbamazepine , fluconazole , ketoconazole , voriconazole , erythromycin , clarithromycin . Patients treat investigational drug .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>tacrolimus</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>formulation</keyword>
	<keyword>daily</keyword>
	<keyword>twice daily</keyword>
	<keyword>renal transplant recipient</keyword>
	<keyword>Kidney transplantation</keyword>
</DOC>